Keywords
erythropoietin
high altitude
low altitude
renal replacement therapy
chronic kidney disease
How to Cite
Abstract
Introduction: During the last decades the use of erythropoiesis stimulating agents has significantly diminished the prevalence of anemia in patients receiving chronic hemodialysis. Currently, residing at higher altitudes is associated with higher levels of endogenous erythropoietin.
Objective: This study aims to analyze how residing at higher altitudes influences the requirements of exogenous erythropoietin in patients receiving hemodialysis as renal replacement therapy.
Methodology: Descriptive observational cross-section, including adult patients from three Ecuadorian centers, receiving chronic hemodialysis, between January and June 2020. Patients were classified into two groups regarding the altitude of residence: those living at low-lying regions (<2000 masl, Santo Domingo de los Tsachilas and Tena) and those living at high altitude (>2000 masl, Quito).
Results: We included 580 patients, 45.5% in the high-altitude group and 54.5% at low-lying regions. Median exogenous erythropoietin dose was higher in low-lying regions (22000 international units) versus high altitude (17333.3 international units) (P=0.00003) and the proportion of patients without erythropoietin requirement was higher in high altitude (21.6%), compared to low regions (1.0%) (P<0.01). The multivariate analysis associated residing in low regions (HR 58.9, P<0.01), age (HR 0.98, P=0.03) and Kt/V (HR 38.5, P<0.01) with higher exogenous erythropoietin requirements. Additionally, among patients who required erythropoietin, residing in lower altitudes was linked with a need for exogenous erythropoietin doses exceeding 15000 international units per week (HR 1.92, P=0.001).
Conclusion: In Ecuadorian patients receiving hemodialysis, living at high altitude is associated with a reduced requirement of exogenous erythropoietin compared with those patients residing in low-lying regions.
References
Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med. 2021;8:642296. https://doi.org/10.3389/fmed.2021.642296
Pertuz-Pinzón A, Ismael-Garcia C, Muñoz-Gómez C, Rico-Fontalvo J, Daza-Arnedo R, Pájaro-Galvis N, et al. Anemia en Enfermedad Renal. Arch Med. 2021;17(2):1–8.
Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence. 2008; 2:195-200. https://doi.org/10.2147/PPA.S2356
Zadrazil J, Horak P. Pathophysiology of anemia in chronic kidney diseases: A review. Biomed Pap. 2015 Jun; 159(2):197-202. https://doi.org/10.5507/bp.2013.093
Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009 Jul; 32(7): 1320-1326. https://doi.org/10.2337/dc08-0779
Srinivasan R, Fredy IC, Chandrashekar S, Saravanan J, Mohanta GP, Manna PK. Assessment of erytropoietin for treatment of anemia in chronic kidney failure- ESRD patients. Biomed Pharmacother. 2016 Aug; 82: 44-48. https://doi.org/10.1016/j.biopha.2016.04.041
Tanhehco YC, Berns JS. Red Blood Cell Transfusion Risks in Patients with End-Stage Renal Disease. Semin Dial. 2012 Sep-Oct; 25(5): 539-44. https://doi.org/10.1111/j.1525-139X.2012.01089.x
Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract. 2017 Sep; 36(3): 209-223. https://doi.org/10.23876/j.krcp.2017.36.3.209
Shahab MH, Saifullah Khan S. Erythropoietin Administration for Anemia Due to Chronic Kidney Disease - Subcutaneous OR Intravenous, What Do We Know So Far? Cureus. 2020 Sep; 12(9): e10358. https://doi.org/10.7759/cureus.10358
Beall CM. Two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc Natl Acad Sci USA. 2007 May 15;104 Suppl 1 (Suppl 1):8655-60. https://doi.org/10.1073/pnas.0701985104
Basu M, Malhotra AS, Pal K, Prasad R, Kumar R, Prasad BAK, et al. Erythropoietin levels in lowlanders and high-altitude natives at 3450 m. Aviat Sp Environ Med. 2007 Oct; 78(10): 963-7. https://doi.org/10.3357/ASEM.2085.2007
Coppel J, Hennis P, Gilbert-Kawai E, Grocott MPW. The physiological effects of hypobaric hypoxia versus normobaric hypoxia: A systematic review of crossover trials. Extreme Physiol Med. 2015 Feb 26;4:2. https://doi.org/10.1186/s13728-014-0021-6
Beall CM. Tibetan and Andean patterns of adaptation to high-altitude hypoxia. Hum Biol. 2000 Feb; 72(1): 201-28.
Peralta González MA, Zanguña Fonseca LF, Cruz Rubio SG. Niveles de eritropoyetina y reticulocitos en residentes de bajas alturas migrantes a medianas altura. Rev la Univ Ind Santander Salud. 2017; 49(4): 535-9. https://doi.org/10.18273/revsal.v49n4-2017002
Watts D, Gaete D, Rodriguez D, Hoogewijs D, Rauner M, Sormendi S, et al. Hypoxia pathway proteins are master regulators of erythropoiesis. Int J Mol Sci. 2020 Nov; 21(21):8131. https://doi.org/10.3390/ijms21218131
Shih HM, Wu CJ, Lin SL. Physiology and pathophysiology of renal erythropoietin-producing cells. J Formos Med Assoc. 2018 Nov; 117(11): 955-963. https://doi.org/10.1016/j.jfma.2018.03.017
Mimura I, Tanaka T, Nangaku M. How the Target Hemoglobin of Renal Anemia Should Be? Nephron. 2015;131(3):202-9. https://doi.org/10.1159/000440849
Sibbel S, Maroni BJ, Brunelli SM. The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients. J Nephrol. 2017; 30(6):821-829. https://doi.org/10.1007/s40620-016-0350-1
Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul;19(7):1389-1395. https://doi.org/10.1681/ASN.2007111181
Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, et al. Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2019 Nov;74(5):713-715. https://doi.org/10.1053/j.ajkd.2019.03.432
Hurtado A, Palacios AM, Figueroa J, Gonzales-Polar J, Kaluguina de Yrigoin A, Lopera MT. Niveles de hemoglobina en pacientes en hemodiálisis a nivel del mar y a mayor altitud, y su relación con la calidad de vida. Rev Soc Peru Med Interna. 2013;26(4):171–6.
Bravo-Jaimes K, Loescher VY, Canelo-Aybar C, Rojas-Camayo J, Mejia CR, Schult S, et al. Effect of altitude on mortality of end-stage renal disease patients on hemodialysis in Peru. Clin Kidney J. 2021 Mar;14(3):998-1003. https://doi.org/10.1093/ckj/sfaa056
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.